Self-amplifying mRNA vaccines expressing multiple conserved influenza antigens confer protection against homologous and heterosubtypic viral challenge

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Magini, Diletta ^a,b,d   Giovani, Cinzia ^a,e   Mangiavacchi, Simona ^a,e   MacCari, Silvia ^a,e   Cecchi, Raffaella ^a,e   Ulmer, Jeffrey B ^c,f   De Gregorio, Ennio ^a,e   Geall, Andrew J ^c,g   Brazzoli, Michela ^a,e   Bertholet, Sylvie ^a,e  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b UNIVERSITY OF SIENA   (Italy)

^c Novartis Vaccines Inc   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

^e GSK   (Italy)

^f GLAXOSMITHKLINE   (United States)

^g Avidity NanoMedicines   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; LIPID NANOPARTICLE; MATRIX PROTEIN; MATRIX PROTEIN 1; MESSENGER RNA; MONOVALENT INACTIVATED INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; NUCLEOPROTEIN; SELF AMPLIFYING MESSENGER RNA; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; CORE PROTEIN; INACTIVATED VACCINE; M1 PROTEIN, INFLUENZA A VIRUS; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; HELPER CELL; IMMUNE SYSTEM; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; SURVIVAL; VIRUS TITRATION; ANIMAL; CELL LINE; CONSERVED SEQUENCE; GENE AMPLIFICATION; GENE EXPRESSION; GENE VECTOR; GENETICS; HAMSTER; IMMUNOLOGY; INFLUENZA A VIRUS; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); LUNG; PHYSIOLOGY;

ANIMALS; ANTIGENS, VIRAL; CELL LINE; CONSERVED SEQUENCE; CRICETINAE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC VECTORS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; LUNG; MICE; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, INACTIVATED; VIRAL CORE PROTEINS; VIRAL MATRIX PROTEINS;

EID: 84984822445     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0161193     Document Type: Article

References (68)

1. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine. 2007; 25(27):5086-96. Epub 2007/06/05. doi: 10.1016/j.vaccine.2007.03.046 PMID: 17544181.
2. Soema PC, Kompier R, Amorij JP, Kersten GF. Current and next generation influenza vaccines: Formulation and production strategies. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2015. Epub 2015/06/07. doi: 10.1016/j.ejpb.2015.05.023 PMID: 26047796.
3. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. Journal of medical virology. 2000; 61 (1):94-9. Epub 2000/04/04. PMID: 10745239.
4. Cowling BJ, Ng S, Ma ES, Cheng CK, Wai W, Fang VJ, et al. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2010; 51 (12):1370-9. Epub 2010/11/12. doi: 10.1086/657311 PMID: 21067351.
5. Ansaldi F, Zancolli M, Durando P, Montomoli E, Sticchi L, Del Giudice G, et al. Antibody response against heterogeneous circulating influenza virus strains elicited by MF59-and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates. Vaccine. 2010; 28(25):4123-9. Epub 2010/05/04. doi: 10.1016/j.vaccine.2010.04.030 PMID: 20433807.
6. Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R. Aflunov(R): a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert opinion on biological therapy. 2013; 13 (1):121-35. Epub 2012/11/30. doi: 10.1517/14712598.2013.748030 PMID: 23189937.
7. Orsi A, Ansaldi F, de Florentiis D, Ceravolo A, Parodi V, Canepa P, et al. Cross-protection against drifted influenza viruses: options offered by adjuvanted and intradermal vaccines. Human vaccines & immunotherapeutics. 2013; 9(3):582-90. Epub 2013/01/09. PMID: 23295230; PubMed Central PMCID: PMCPmc3891715.
8. Lambe T, Carey JB, Li Y, Spencer AJ, van Laarhoven A, Mullarkey CE, et al. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1. Scientific reports. 2013; 3:1443. Epub 2013/03/15. doi: 10.1038/srep01443 PMID: 23485942; PubMed Central PMCID: PMCPmc3595699.
9. Epstein SL, Tumpey TM, Misplon JA, Lo CY, Cooper LA, Subbarao K, et al. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerging infectious diseases. 2002; 8(8):796-801. Epub 2002/07/27. doi: 10.3201/eid0805.010476 PMID: 12141964; PubMed Central PMCID: PMCPmc2732511.
10. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259(5102):1745-9. PMID: 8456302.
11. Gerhard W, Mozdzanowska K, Furchner M, Washko G, Maiese K. Role of the B-cell response in recovery of mice from primary influenza virus infection. Immunological reviews. 1997; 159:95-103. Epub 1998/01/07. PMID: 9416505.
12. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, et al. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. Journal of virology. 1998; 72 (7):5648-53. Epub 1998/06/17. PMID: 9621023; PubMed Central PMCID: PMCPmc110229.
13. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. Journal of immunology (Baltimore, Md: 1950). 2008; 181(6):4168-76. Epub 2008/09/05. PMID: 18768874; PubMed Central PMCID: PMCPmc2590646.
14. Epstein SL, Kong WP, Misplon JA, Lo CY, Tumpey TM, Xu L, et al. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005; 23(46-47):5404-10. doi: 10.1016/j.vaccine.2005.04.047 PMID: 16011865.
15. Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Human vaccines. 2007; 3(5):157-64. Epub 2007/07/20. PMID: 17637571.
16. Okuda K, Ihata A, Watabe S, Okada E, Yamakawa T, Hamajima K, et al. Protective immunity against influenza A virus induced by immunization with DNA plasmid containing influenza M gene. Vaccine. 2001; 19(27):3681-91. Epub 2001/06/08. PMID: 11395202.
17. Chen Q, Kuang H, Wang H, Fang F, Yang Z, Zhang Z, et al. Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus. Virus genes. 2009; 38 (1):30-8. Epub 2008/12/11. doi: 10.1007/s11262-008-0305-2 PMID: 19067149.
18. Altstein AD, Gitelman AK, Smirnov YA, Piskareva LM, Zakharova LG, Pashvykina GV, et al. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Archives of virology. 2006; 151(5):921-31. Epub 2005/11/18. doi: 10.1007/s00705-005-0676-9 PMID: 16292596.
19. Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, et al. MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PloS one. 2014; 9(2):e88340. Epub 2014/02/14. doi: 10.1371/journal.pone.0088340 PMID: 24523886; PubMed Central PMCID: PMCPmc3921149.
20. Jeon SH, Ben-Yedidia T, Arnon R. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine. 2002; 20(21-22):2772-80. Epub 2002/05/30. PMID: 12034104.
21. Tamura S, Miyata K, Matsuo K, Asanuma H, Takahashi H, Nakajima K, et al. Acceleration of influenza virus clearance by Th1 cells in the nasal site of mice immunized intranasally with adjuvant-combined recombinant nucleoprotein. Journal of immunology (Baltimore, Md: 1950). 1996; 156(10):3892-900. Epub 1996/05/15. PMID: 8621928.
22. Zhirnov OP, Isaeva EI, Konakova TE, Thoidis G, Piskareva LM, Akopova II, et al. Protection against mouse and avian influenza A strains via vaccination with a combination of conserved proteins NP, M1 and NS1. Influenza and other respiratory viruses. 2007; 1(2):71-9. Epub 2008/09/12. doi: 10.1111/j. 1750-2659.2007.00010.x PMID: 18784792; PubMed Central PMCID: PMCPmc2040185.
23. Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. The Journal of infectious diseases. 2011; 204(6):845-53. Epub 2011/08/19. doi: 10.1093/infdis/jir436 PMID: 21846636; PubMed Central PMCID: PMCPmc3156924.
24. Belshe RB, Edwards KM, Vesikari T, Black SV, Walker RE, Hultquist M, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. The New England journal of medicine. 2007; 356(7):685-96. Epub 2007/02/16. doi: 10.1056/NEJMoa065368 PMID: 17301299.
25. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. The New England journal of medicine. 2009; 361 (13):1260-7. Epub 2009/09/25. doi: 10.1056/NEJMoa0808652 PMID: 19776407.
26. Petsch B, Schnee M, Vogel AB, Lange E, Hoffmann B, Voss D, et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nature biotechnology. 2012; 30 (12):1210-6. doi: 10.1038/nbt.2436 PMID: 23159882.
27. Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, et al. Potent Immune Responses in Rhesus Macaques Induced by Nonviral Delivery of a Self-amplifying RNA Vaccine Expressing HIV Type 1 Envelope With a Cationic Nanoemulsion. The Journal of infectious diseases. 2014. Epub 2014/09/23. doi: 10.1093/infdis/jiu522 PMID: 25234719.
28. Brito LA, Chan M, Shaw CA, Hekele A, Carsillo T, Schaefer M, et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Molecular therapy: the journal of the American Society of Gene Therapy. 2014; 22(12):2118-29. Epub 2014/07/17. doi: 10.1038/mt.2014.133 PMID: 25027661.
29. Hekele A, Bertholet S, Archer J, Gibson DG, Palladino G, Brito LA, et al. Rapidly produced SAM((R)) vaccine against H7N9 influenza is immunogenic in mice. Emerging microbes & infections. 2013; 2(8): e52. Epub 2013/08/01. doi: 10.1038/emi.2013.54 PMID: 26038486.
30. Brazzoli M, Magini D, Bonci A, Buccato S, Giovani C, Kratzer R, et al. Induction of broad-based immunity and protective efficacy by self-amplifying mRNA vaccines encoding influenza virus hemagglutinin. Journal of virology. 2015. Epub 2015/10/16. doi: 10.1128/jvi.01786-15 PMID: 26468547.
31. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(36):14604-9. Epub 2012/08/22. doi: 10.1073/pnas.1209367109 PMID: 22908294; PubMed Central PMCID: PMCPmc3437863.
32. Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. Journal of virology. 2003; 77(19):10394-403. Epub 2003/09/13. PMID: 12970424; PubMed Central PMCID: PMCPmc228391.
33. Geall AJ, Verma A, Otten GR, Shaw CA, Hekele A, Banerjee K, et al. Nonviral delivery of self-amplifying RNA vaccines. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109(36):14604-9. doi: 10.1073/pnas.1209367109 PMID: 22908294; PubMed Central PMCID: PMCPMC3437863.
34. Lazzaro S, Giovani C, Mangiavacchi S, Magini D, Maione D, Baudner B, et al. CD8 T cells priming upon mRNA vaccination is restricted to bone marrow-derived antigen presenting cells and may involves antigen transfer from myocytes. Immunology. 2015. Epub 2015/07/16. doi: 10.1111/imm.12505 PMID: 26173587.
35. Jin H, Xiao C, Chen Z, Kang Y, Ma Y, Zhu K, et al. Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. Biochemical and biophysical research communications. 2005; 328(4):979-86. Epub 2005/02/15. doi: 10.1016/j.bbrc.2005.01.048 PMID: 15707974.
36. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nature protocols. 2008; 3(6):1101-8. PMID: 18546601.
37. Jungblut M, Oeltze K, Zehnter I, Hasselmann D, Bosio A. Standardized preparation of single-cell suspensions from mouse lung tissue using the gentleMACS Dissociator. Journal of visualized experiments: JoVE. 2009;(29:). Epub 2009/07/04. doi: 10.3791/1266 PMID: 19574953; PubMed Central PMCID: PMCPmc2798855.
38. Liacopoulos P, Ben-Efraim S. Antigenic competition. Prog Allergy. 1975; 18:97-204. PMID: 50601.
39. Manoj S, Babiuk LA, van Drunen Littel-van den Hurk S. Immunization with a dicistronic plasmid expressing a truncated form of bovine herpesvirus-1 glycoprotein D and the amino-terminal subunit of glycoprotein B results in reduced gB-specific immune responses. Virology. 2003; 313(1):296-307. PMID: 12951041.
40. Szewczyk B, Bienkowska-Szewczyk K, Krol E. Introduction to molecular biology of influenza a viruses. Acta biochimica Polonica. 2014; 61(3):397-401. Epub 2014/09/03. PMID: 25180226.
41. Zaritskaya L, Shurin MR, Sayers TJ, Malyguine AM. New flow cytometric assays for monitoring cellmediated cytotoxicity. Expert review of vaccines. 2010; 9(6):601-16. Epub 2010/06/04. doi: 10.1586/erv.10.49 PMID: 20518716; PubMed Central PMCID: PMCPmc2911950.
42. Wang W, Li R, Deng Y, Lu N, Chen H, Meng X, et al. Protective efficacy of the conserved NP, PB1, and M1 proteins as immunogens in DNA-and vaccinia virus-based universal influenza A virus vaccines in mice. Clinical and vaccine immunology: CVI. 2015. Epub 2015/04/03. doi: 10.1128/cvi.00091-15 PMID: 25834017.
43. Sun JC, Williams MA, Bevan MJ. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol. 2004; 5(9):927-33. Epub 2004/08/10. doi: 10.1038/ni1105 PMID: 15300249; PubMed Central PMCID: PMCPMC2776074.
44. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med. 1998; 188(12):2199-204. Epub 1998/12/22. PMID: 9858506; PubMed Central PMCID: PMCPMC2212425.
45. Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, et al. Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cellmediated responses. Molecular therapy: the journal of the American Society of Gene Therapy. 2014; 22(1):233-8. Epub 2013/07/09. doi: 10.1038/mt.2013.162 PMID: 23831594; PubMed Central PMCID: PMCPmc3978791.
46. Furuya Y. Return of inactivated whole-virus vaccine for superior efficacy. Immunology and cell biology. 2012; 90(6):571-8. Epub 2011/08/17. doi: 10.1038/icb.2011.70 PMID: 21844883.
47. Hamm S, Heit A, Koffler M, Huster KM, Akira S, Busch DH, et al. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo. Int Immunol. 2007; 19 (3):297-304. doi: 10.1093/intimm/dxl146 PMID: 17289655.
48. Jelinek I, Leonard JN, Price GE, Brown KN, Meyer-Manlapat A, Goldsmith PK, et al. TLR3-specific double-stranded RNA oligonucleotide adjuvants induce dendritic cell cross-presentation, CTL responses, and antiviral protection. J Immunol. 2011; 186(4):2422-9. doi: 10.4049/jimmunol.1002845 PMID: 21242525; PubMed Central PMCID: PMC3078629.
49. Sridhar S, Begom S, Bermingham A, Hoschler K, Adamson W, Carman W, et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nature medicine. 2013; 19(10):1305-12. Epub 2013/09/24. doi: 10.1038/nm.3350 PMID: 24056771.
50. Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature medicine. 2012; 18(2):274-80. Epub 2012/01/31. doi: 10.1038/nm.2612 PMID: 22286307.
51. Johansson DX, Ljungberg K, Kakoulidou M, Liljestrom P. Intradermal electroporation of naked replicon RNA elicits strong immune responses. PloS one. 2012; 7(1):e29732. Epub 2012/01/13. doi: 10.1371/journal.pone.0029732 PMID: 22238645; PubMed Central PMCID: PMCPmc3251598.
52. Donnelly JJ, Friedman A, Ulmer JB, Liu MA. Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination. Vaccine. 1997; 15(8):865-8. Epub 1997/06/01. PMID: 9234535.
53. McMichael AJ, Gotch FM, Noble GR, Beare PA. Cytotoxic T-cell immunity to influenza. The New England journal of medicine. 1983; 309(1):13-7. Epub 1983/07/07. doi: 10.1056/nejm198307073090103 PMID: 6602294.
54. Grebe KM, Yewdell JW, Bennink JR. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes and infection/Institut Pasteur. 2008; 10(9):1024-9. Epub 2008/07/30. doi: 10.1016/j. micinf.2008.07.002 PMID: 18662798; PubMed Central PMCID: PMCPmc2584237.
55. Gianfrani C, Oseroff C, Sidney J, Chesnut RW, Sette A. Human memory CTL response specific for influenza A virus is broad and multispecific. Human immunology. 2000; 61(5):438-52. Epub 2000/04/25. PMID: 10773346.
56. Jameson J, Cruz J, Ennis FA. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. Journal of virology. 1998; 72(11):8682-9. Epub 1998/10/10. PMID: 9765409; PubMed Central PMCID: PMCPmc110281.
57. Plotnicky H, Cyblat-Chanal D, Aubry JP, Derouet F, Klinguer-Hamour C, Beck A, et al. The immunodominant influenza matrix T cell epitope recognized in human induces influenza protection in HLA-A2/K (b) transgenic mice. Virology. 2003; 309(2):320-9. PMID: 12758178.
58. Morrison J, Elvin J, Latron F, Gotch F, Moots R, Strominger JL, et al. Identification of the nonamer peptide from influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. European journal of immunology. 1992; 22(4):903-7. Epub 1992/04/01. doi: 10.1002/eji. 1830220404 PMID: 1372560.
59. Lehner PJ, Wang EC, Moss PA, Williams S, Platt K, Friedman SM, et al. Human HLA-A0201-restricted cytotoxic T lymphocyte recognition of influenza A is dominated by T cells bearing the V beta 17 gene segment. J Exp Med. 1995; 181(1):79-91. PMID: 7807026; PubMed Central PMCID: PMC2191841.
60. Cukalac T, Chadderton J, Zeng W, Cullen JG, Kan WT, Doherty PC, et al. The influenza virus-specific CTL immunodominance hierarchy in mice is determined by the relative frequency of high-avidity T cells. J Immunol. 2014; 192(9):4061-8. doi: 10.4049/jimmunol.1301403 PMID: 24696232.
61. La Gruta NL, Thomas PG, Webb AI, Dunstone MA, Cukalac T, Doherty PC, et al. Epitope-specific TCRbeta repertoire diversity imparts no functional advantage on the CD8+ T cell response to cognate viral peptides. Proc Natl Acad Sci U S A. 2008; 105(6):2034-9. doi: 10.1073/pnas.0711682102 PMID: 18238896; PubMed Central PMCID: PMC2538877.
62. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011; 52(1):1-7. doi: 10.1093/cid/ciq015 PMID: 21148512; PubMed Central PMCID: PMC3060888.
63. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, et al. Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012; 55(1):19-25. Epub 2012/03/24. doi: 10.1093/cid/cis327 PMID: 22441650; PubMed Central PMCID: PMCPmc3369564.
64. Mullarkey CE, Boyd A, van Laarhoven A, Lefevre EA, Veronica Carr B, Baratelli M, et al. Improved adjuvanting of seasonal influenza vaccines: preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine. European journal of immunology. 2013; 43(7):1940-52. Epub 2013/04/17. doi: 10.1002/eji.201242922 PMID: 23589155.
65. Maisonneuve C, Bertholet S, Philpott DJ, De Gregorio E. Unleashing the potential of NOD-and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A. 2014; 111(34):12294-9. doi: 10.1073/pnas. 1400478111 PMID: 25136133; PubMed Central PMCID: PMC4151741.
66. Deering RP, Kommareddy S, Ulmer JB, Brito LA, Geall AJ. Nucleic acid vaccines: prospects for nonviral delivery of mRNA vaccines. Expert opinion on drug delivery. 2014; 11(6):885-99. Epub 2014/03/29. doi: 10.1517/17425247.2014.901308 PMID: 24665982.
67. Altenburg AF, Kreijtz JH, de Vries RD, Song F, Fux R, Rimmelzwaan GF, et al. Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases. Viruses. 2014; 6(7):2735-61. doi: 10.3390/v6072735 PMID: 25036462; PubMed Central PMCID: PMC4113791.
68. Uematsu Y, Vajdy M, Lian Y, Perri S, Greer CE, Legg HS, et al. Lack of interference with immunogenicity of a chimeric alphavirus replicon particle-based influenza vaccine by preexisting antivector immunity. Clin Vaccine Immunol. 2012; 19(7):991-8. doi: 10.1128/CVI.00031-12 PMID: 22623651; PubMed Central PMCID: PMC3393363.